Compass Pathways plc Releases Presentation on Transforming Mental Health Care with Innovative Treatments for TRD and PTSD

Reuters

2025/08/08

Compass Pathways plc Releases Presentation on Transforming Mental Health Care with Innovative Treatments for TRD and PTSD

Compass Pathways plc recently held an investor presentation highlighting their ongoing efforts in transforming mental health care. The company is currently conducting a Phase 3 Treatment-Resistant Depression $(TRD.UK)$ program with their lead product candidate, COMP360 psilocybin treatment. The first pivotal trial (COMP005) has achieved its 6-week primary endpoint, while data from the second pivotal trial (COMP006) is expected in the second half of 2026. Additionally, their Phase 2 TRD program has been published in The New England Journal of Medicine, and positive top-line data from a Phase 2 PTSD study was reported in the second quarter of 2024, with a late-stage clinical study in development. As of June 30, 2025, Compass Pathways reported a cash position of $222 million. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to generate this news brief on August 06, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2557421567"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557421567\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557421567?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-08 00:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557421567","market":"us","top_or_hot":-1,"title":"Compass Pathways plc Releases Presentation on Transforming Mental Health Care with Innovative Treatments for TRD and PTSD","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Compass Pathways plc Releases Presentation on Transforming Mental Health Care with Innovative Treatments for TRD and PTSD\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Compass Pathways plc recently held an investor presentation highlighting their ongoing efforts in transforming mental health care. The company is currently conducting a Phase 3 Treatment-Resistant Depression <a href=\"https://laohu8.com/S/TRD.UK\">$(TRD.UK)$</a> program with their lead product candidate, COMP360 psilocybin treatment. The first pivotal trial (COMP005) has achieved its 6-week primary endpoint, while data from the second pivotal trial (COMP006) is expected in the second half of 2026. Additionally, their Phase 2 TRD program has been published in The <a href=\"https://laohu8.com/S/NEWEN\">New England</a> Journal of Medicine, and positive top-line data from a Phase 2 PTSD study was reported in the second quarter of 2024, with a late-stage clinical study in development. As of June 30, 2025, Compass Pathways reported a cash position of $222 million. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to generate this news brief on August 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Compass Pathways plc Releases Presentation on Transforming Mental Health Care with Innovative Treatments for TRD and PTSD</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCompass Pathways plc Releases Presentation on Transforming Mental Health Care with Innovative Treatments for TRD and PTSD\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-08 00:07</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Compass Pathways plc Releases Presentation on Transforming Mental Health Care with Innovative Treatments for TRD and PTSD\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Compass Pathways plc recently held an investor presentation highlighting their ongoing efforts in transforming mental health care. The company is currently conducting a Phase 3 Treatment-Resistant Depression <a href=\"https://laohu8.com/S/TRD.UK\">$(TRD.UK)$</a> program with their lead product candidate, COMP360 psilocybin treatment. The first pivotal trial (COMP005) has achieved its 6-week primary endpoint, while data from the second pivotal trial (COMP006) is expected in the second half of 2026. Additionally, their Phase 2 TRD program has been published in The <a href=\"https://laohu8.com/S/NEWEN\">New England</a> Journal of Medicine, and positive top-line data from a Phase 2 PTSD study was reported in the second quarter of 2024, with a late-stage clinical study in development. As of June 30, 2025, Compass Pathways reported a cash position of $222 million. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to generate this news brief on August 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nNDL9k4dPP:1","article_id":"2557421567","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557421567","pubTimestamp":1754582837,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Compass Pathways plc recently held an investor presentation highlighting their ongoing efforts in transforming mental health care. The company is currently conducting a Phase 3 Treatment-Resistant Depression  program with their lead product candidate, COMP360 psilocybin treatment. The first pivotal trial  has achieved its 6-week primary endpoint, while data from the second pivotal trial  is expected in the second half of 2026. Additionally, their Phase 2 TRD program has been published in The New England Journal of Medicine, and positive top-line data from a Phase 2 PTSD study was reported in the second quarter of 2024, with a late-stage clinical study in development. As of June 30, 2025, Compass Pathways reported a cash position of $222 million. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generat","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CMPS":"COMPASS Pathways plc"},"translate_title":"Compass Pathways plc发布关于通过TRD和PTSD创新疗法转变心理卫生保健的演示文稿","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMPS":0.9},"content_text":"Compass Pathways plc Releases Presentation on Transforming Mental Health Care with Innovative Treatments for TRD and PTSD\n    \n\n        Compass Pathways plc recently held an investor presentation highlighting their ongoing efforts in transforming mental health care. The company is currently conducting a Phase 3 Treatment-Resistant Depression $(TRD.UK)$ program with their lead product candidate, COMP360 psilocybin treatment. The first pivotal trial (COMP005) has achieved its 6-week primary endpoint, while data from the second pivotal trial (COMP006) is expected in the second half of 2026. Additionally, their Phase 2 TRD program has been published in The New England Journal of Medicine, and positive top-line data from a Phase 2 PTSD study was reported in the second quarter of 2024, with a late-stage clinical study in development. As of June 30, 2025, Compass Pathways reported a cash position of $222 million. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to generate this news brief on August 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}